Clinical Research Directory
Browse clinical research sites, groups, and studies.
Insulin Regulation of Lipolysis and Lipolysis Proteins
Sponsor: Mayo Clinic
Summary
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2018-11-12
Completion Date
2026-12-31
Last Updated
2026-01-28
Healthy Volunteers
Yes
Conditions
Interventions
Immediate weight loss
Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
Pioglitazone
Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
Deferred weight loss
Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
Placebo
Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States